Quoin Pharmaceuticals, Ltd. (QNRX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$3.1M
Cash & Equivalents
$4.9M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$9M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-30 | Phase3 Readout | — |
| 2027-01-31 | Phase3 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05789056 | Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome | PHASE3 | Recruiting | 20 |
| NCT07538583 | Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | PHASE3 | Recruiting | 16 |
| NCT05521438 | Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome | PHASE3 | Active Not Recruiting | 30 |
| NCT06953466 | Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | PHASE3 | Recruiting | 8 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.